And in a labor market where replacing a single employee can cost up to 200% of their annual salary, the math on covering this medication starts to look very different very quickly
The neck area slims considerably
In a single piece, he concisely captures: the state of the field the most important clinical trials where the pipeline is headed These Clinical trials are raising the bar and expanding future treatment options: Retatrutide ~24% weight loss (triple agonist) MariTide 1216% weight loss (GLP-1 + GIP antagonist) CagriSema up to 20% weight loss + ~2% HbA1c drop Orforglipron oral GLP-1, HbA1c 1.5%, weight 7.6% IcoSema weekly semaglutide + once-weekly insulin Even more exciting
In December 2014, the Food and Drug Administration (FDA) approved liraglutide for weight loss, and semaglutide was approved for diabetes in 2017 and obesity in 2021, opening a new era of obesity treatment
Those findings are promising but remain preliminary and are not established reasons to prescribe a GLP-1 solely for a skin condition
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
